

Three New Flavonoid Glycosides Isolated from *Elsholtzia bodinieri*

Rong-Tao LI,^{*,a,c} Jin-Tong LI,^b Jing-Kun WANG,^b Quan-Bin HAN,^a Zhao-Yun ZHU,^b and Han-Dong SUN^{*,a}

^aState Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences; Kunming, Yunnan 650204, P. R. China; ^bYunnan Institute of Materia Medica; Kunming 650111, P. R. China; and ^cKunming University of Science and Technology; 253 Xuefu Road, Kunming 650093, P. R. China.

Received October 22, 2007; accepted January 7, 2008; published online January 29, 2008

Three new flavonoid glycosides, eriodictyol 7-*O*-(6''-feruloyl)- β -D-glucopyranoside (**1**), eriodictyol 7-*O*-[6''-(3'''-hydroxy-4'''-methoxy cinnamoyl)]- β -D-glucopyranoside (**2**), and luteolin 7-*O*-[6''-(3'''-hydroxy-4'''-methoxy cinnamoyl)]- β -D-glucopyranoside (**3**), and eight known flavonoids were isolated from the whole plants of *Elsholtzia bodinieri*. The structures of the 3 new compounds were elucidated on the basis of extensive spectroscopic analysis.

Key words *Elsholtzia bodinieri*; Labiatae; flavonoid

Elsholtzia bodinieri VANIOT, belonging to the taxonomically diverse group of the family Labiatae, is a medicinal plant growing in Yunnan and Guizhou Provinces in China. It is commonly known as "yashuacao" and has been used as a traditional Chinese medicine for the treatment of cough, headache, pharyngitis, fever and hepatitis.¹⁾ An earlier study on this plant led to the isolation of two new triterpene glycosides, hederagenin 3-*O*- β -D-xylopyranoside and dodecandral 3-*O*- β -D-xylopyranoside.²⁾ Inspired by the efficacious treatment for influenza³⁾ and by lack of systematic investigation on the chemical constituents on this plant, we investigated the EtOAc extract of the whole plants of *E. bodinieri*. In a preceding paper, we have described the elucidation of two novel triterpenoid glycosides, bodinosides A and B.⁴⁾ We report herein on the isolation and structural determination of three new flavonoid glycosides, eriodictyol 7-*O*-(6''-feruloyl)- β -D-glucopyranoside (**1**), eriodictyol 7-*O*-[6''-(3'''-hydroxy-4'''-methoxy cinnamoyl)]- β -D-glucopyranoside (**2**), and luteolin 7-*O*-[6''-(3'''-hydroxy-4'''-methoxy cinnamoyl)]- β -D-glucopyranoside (**3**), together with eight known flavonoids, luteolin 7-*O*-(6''-feruloyl)- β -D-glucopyranoside (**4**), eriodictyol, miscanthoside, luteolin, glucoluteolin, apigenin-7-glucoside, chrysin and apigenin from the same extract.




Fig. 1. Structures of Compounds 1—4

Results and Discussion

Compound **1** was isolated as yellow amorphous powder, whose molecular formula of C₃₁H₃₀O₁₄ was determined on the basis of HR-FAB-MS (negative-ion mode) analysis ([M-H]⁻, 625.1543) and ¹³C-NMR spectrum, indicating 17 degrees of unsaturation. The IR spectrum indicated the presence of OH (3420 cm⁻¹), α,β -unsaturated carbonyl (1690 cm⁻¹) and aromatic rings (1642, 1516, 1453 cm⁻¹). The UV spectrum exhibited maximum absorptions at 327, 285 and 203 nm. Examination of the ¹H- and ¹³C-NMR spectral data of **1** (Tables 1, 2) indicated that the molecule consisted of a flavanone, a glucose, a 1,3,4-trisubstituted benzene ring, a *trans*- α,β -unsaturated ester, and a methoxyl moieties.

The ¹H-NMR spectrum suggested that **1** has an aglycon eriodictyol. Signals at δ_{H} 7.51 (br s, H-2'), 7.28 (d, *J*=8.0 Hz, H-5'), and 7.03 (br d, *J*=8.0 Hz, H-6') are characteristic for a 3,4-disubstituted B ring of an eriodictyol unit. Two sets of doublets at δ_{H} 6.69 (d, *J*=1.5 Hz) and 6.46 (d, *J*=1.5 Hz) originated from the signals of H-6 and H-8 in ring A of an eriodictyol. This was in sound agreement with the ¹³C-NMR spectrum. The six carbon signals of the sugar moiety were at δ_{C} 101.6, 78.3, 75.8, 74.7, 71.3 and 64.4, suggesting that **1** was an eriodictyol glycoside. The presence of the β -D-glucopyranosyl moiety was supported by the ¹³C-NMR data and further confirmed by the acid hydrolysis of **1**, which resulted in a release of glucose identified by HPTLC comparisons of the hydrolyzate with an authentic sugar sample. The configuration of the glucopyranosyl was assigned to be β -D based on the coupling constant of the anomeric proton. The glucosyl residue was located at the 7-*O*-position of the aglycon eriodictyol by the appearance of HMBC cross peaks of the glucosyl anomeric proton H-1'' (δ_{H} 5.70, d, *J*=7.6 Hz) with the carbon signal at δ_{C} 166.5 (C-7).

From these data, the substituent at C-7 of the aglycon moiety gave a pattern of the ¹³C-NMR signals similar to those in miscanthoside, except for the presence of an additional 3,4-disubstituted coumaroyl unit, which was confirmed by the HMBC correlations shown in Fig. 2. The *trans*-substitution at the olefinic protons (H-7''' and H-8''') of 3,4-substituted coumaroyl was established from the large coupling (*J*=15.9 Hz). Compared with the ¹³C-NMR of miscanthoside, the C-5'' resonance of **1** was shifted upfield by 3.2 ppm,

* To whom correspondence should be addressed. e-mail: hdsun@mail.kib.ac.cn

Table 1. $^1\text{H-NMR}$ Data of Compounds **1**–**3**^{a)}

Position	1	2	3
2	5.40 (d, $J=14.6$)	5.38 (d, $J=14.6$)	—
3a	2.86 (d, $J=17.1$)	2.85 (d, $J=17.1$)	6.83 (s)
3b	3.23 (dd, $J=17.1, 14.6$)	3.22 (dd, $J=17.1, 14.6$)	—
6	6.69 (d, $J=1.5$)	6.71 (d, $J=2.3$)	6.95 (d, $J=2.5$)
8	6.46 (d, $J=1.5$)	6.44 (d, $J=2.3$)	6.90 (d, $J=2.5$)
2'	7.51 (br s)	7.50 (br s)	7.86 (d, $J=2.2$)
5'	7.28 (d, $J=8.0$)	7.27 (d, $J=8.0$)	7.12 (d, $J=8.8$)
6'	7.03 (br d, $J=8.0$)	7.05 (br d, $J=8.0$)	7.48 (dd, $J=8.8, 2.2$)
1''	5.70 (d, $J=7.6$)	5.71 (d, $J=7.6$)	5.79 (d, $J=7.8$)
2''–5''	4.26–4.42 (m)	4.24–4.40 (m)	4.26–4.89 (m)
6''a	5.11 (d, $J=11.8$)	5.13 (d, $J=12.1$)	5.20 (d, $J=11.8$)
6''b	4.90 (dd, $J=11.8, 6.0$)	4.92 (dd, $J=12.1, 5.8$)	4.86 (dd, $J=11.8, 5.3$)
2'''	7.27 (s)	7.05 (d, $J=1.5$)	6.97 (s)
5'''	7.21 (d, $J=6.0$)	6.74 (d, $J=5.6$)	7.30 (d, $J=4.0$)
6'''	7.21 (d, $J=6.0$)	7.18 (d, $J=5.6$)	7.13 (overlap)
7'''	7.93 (d, $J=15.9$)	7.95 (d, $J=15.7$)	7.88 (d, $J=15.9$)
8'''	6.69 (d, $J=15.9$)	6.70 (d, $J=15.7$)	6.68 (d, $J=15.9$)
5-OH	12.6 (s)	12.6 (s)	13.5 (s)
–OCH ₃	3.86 (s)	3.89 (s)	3.80 (s)

a) Data were determined at 400 MHz in $\text{C}_2\text{D}_2\text{N}$, chemical shifts are in ppm and coupling constant J in Hz.

Table 2. $^{13}\text{C-NMR}$ Data of Compounds **1**–**3**^{a)}

Position	1	2	3
2	80.0 (d)	80.0 (d)	164.0 (s)
3	43.5 (t)	43.5 (t)	104.0 (d)
4	197.5 (s)	197.5 (s)	183.0 (s)
5	164.7 (s)	164.7 (s)	162.8 (s)
6	97.6 (d)	97.6 (d)	100.7 (d)
7	166.5 (s)	166.5 (s)	165.5 (s)
8	96.8 (d)	96.9 (d)	95.7 (d)
9	163.6 (s)	163.6 (s)	157.8 (s)
10	104.5 (s)	104.5 (s)	106.7 (d)
1'	130.5 (s)	130.5 (s)	122.6 (s)
2'	115.4 (d)	115.4 (d)	114.7 (d)
3'	147.6 (s)	147.6 (s)	149.1 (s)
4'	149.1 (s)	149.4 (s)	152.0 (s)
5'	116.7 (d)	116.7 (d)	116.9 (d)
6'	118.9 (d)	118.9 (d)	119.8 (d)
1''	101.6 (d)	101.6 (d)	101.9 (d)
2''	74.7 (d)	74.7 (d)	74.8 (d)
3''	78.3 (d)	78.3 (d)	78.5 (d)
4''	71.3 (d)	71.3 (d)	71.6 (d)
5''	75.8 (d)	75.8 (d)	75.8 (d)
6''	64.4 (t)	64.4 (t)	64.6 (t)
1'''	126.6 (s)	125.3 (s)	125.2 (s)
2'''	111.6 (d)	106.9 (d)	106.7 (d)
3'''	151.3 (s)	149.4 (s)	149.1 (s)
4'''	148.1 (s)	140.8 (s)	140.7 (s)
5'''	116.9 (d)	115.4 (d)	115.2 (d)
6'''	123.8 (d)	124.0 (d)	124.0 (d)
7'''	146.1 (d)	146.4 (d)	146.2 (d)
8'''	115.1 (d)	115.1 (d)	115.2 (d)
9'''	167.7 (s)	167.7 (s)	167.6 (s)
–OCH ₃	56.1 (q)	56.6 (q)	56.0 (q)

a) Data were determined at 100 MHz in $\text{C}_2\text{D}_2\text{N}$, chemical shifts are in ppm; assignments were confirmed by ^1H – ^1H COSY, HMQC and HMBC.

while the signal attributable to the adjacent C-6'' was shielded downfield by 2.2 ppm, which indicated that the 3,4-substituted coumaroyl was attached to C-6''. This was confirmed by observation of a HMBC cross peak (Fig. 2) between H₂-6'' (δ_{H} 5.11, 4.90) and C-9''' (δ_{C} 167.7).

HMBC cross peaks from H-5''' (δ_{H} 7.21, d, $J=6.0$ Hz) to




Fig. 2. The Key HMBC and NOESY Correlations for Compound **1**
→ HMBC, ↔ NOESY.

C-4''' and C-6''' (δ_{C} 123.8), and from H-7''' (δ_{H} 7.93, d, $J=15.9$ Hz) to C-2''' (δ_{C} 111.6), C-6''', C-8''' (δ_{C} 115.1), and C-9''' (δ_{C} 167.7) were also observed. In addition, a cross-peak correlation was observed between the OCH₃ (δ_{H} 3.86) and C-3'''. This information led to the conclusion that the OCH₃ was located at C-3''', and the OH at C-4'''. This assignment was also supported by the NOESY correlation between the OCH₃ and H-2''.

To determine the absolute configuration of the C2-phenyl group of **1**, the circular dichroism (CD) absorption value was examined. The CD spectrum showed positive Cotton effects around 300 nm and a negative Cotton effect around 350 nm, suggesting that **1** has the C2-phenyl group in the β -orientation and is therefore designated as R.⁵⁾ Thus, the structure of **1** was elucidated as eriodictyol 7-*O*-(6''-feruloyl)- β -D-glucopyranoside.

Compound **2** was analyzed for $\text{C}_{31}\text{H}_{30}\text{O}_{14}$ by negative HR-FAB-MS (m/z 625.1538 $[\text{M}-\text{H}]^-$, the same as that of **1**). The ^1H - and ^{13}C -NMR spectral data of **2** (Tables 1, 2) were strikingly similar to those of **1**. These similarities, together with the fact that **1** and **2** possess identical molecular formulae, suggested a close relationship between these two compounds. In fact, in the NMR spectra of **2**, chemical shift differences were only observed for C-2''' (δ_{H} 7.05, δ_{C} 106.9), C-3''' (δ_{C} 149.4), C-4''' (δ_{C} 140.8), and C-5''' (δ_{H} 6.74, δ_{C} 115.4) in the 3,4-substituted coumaroyl unit. Therefore, it is tentatively assumed that **2** was proposed to exist as an isomer of **1** with different substituted location of OCH₃ and OH at C-3''' and C-4''' in the 3,4-substituted coumaroyl unit.

The proton H-2'' (δ_{H} 7.05, d, $J=1.5$ Hz) of **2** provided a




Fig. 3. The Key HMBC and NOESY Correlations for Compound 2




Fig. 4. The Key HMBC Correlations for Compound 3

starting point to assign the signals of C-1''' (δ_C 125.3), C-3''' (δ_C 149.4), C-4''' (δ_C 140.8), C-6''' (δ_C 124.0), and C-7''' (δ_C 146.4) through the information derived from HMBC correlations (Fig. 3) between H-2''' and C-3''', C-6''', and C-7''', between H-5''' (δ_H 6.74, d, $J=5.6$ Hz) and C-1''', and between the OCH₃ (δ_H 3.89, s) and C-4'''. These findings established the structure of **2** as eriodictyol 7-*O*-[6''-(3'''-hydroxy-4'''-methoxy cinnamoyl)]- β -D-glucopyranoside.

Compound **3** was obtained as yellow amorphous powder. Its empirical formula was confirmed as C₃₁H₂₈O₁₄ by negative HR-FAB-MS and ¹³C-NMR spectroscopic data. A closer comparison of the NMR spectra of **3** with those of **2** indicated that they are closely related (Tables 1, 2). However, the ¹³C-NMR spectrum of **3** lacked the oxygenated methylene and methine signals at C-2 and C-3 (δ_C 80.0, d; 43.5, t, in **2**), showing instead two olefinic carbons at δ_C 164.0 (s) and 104.1 (d). These chemical shifts were in agreement with **3** as a derivative of luteolin glycosides with acylated with 3'''-hydroxy-4'''-methoxy-cinnamic and ferulic acids. HMBC correlations (Fig. 4) of H₂-6''' (δ_H 5.20, 4.86) with C-9''' (δ_C 167.6), of H-7''' (δ_H 7.88, d) with C-2''' (δ_C 106.7), C-6''' (δ_C 124.0) and C-9''', of H-5''' (δ_H 7.30, d) with C-3''' (δ_C 149.1), and of H-8''' (δ_H 6.68, d) with C-6''' (δ_C 124.0) further confirmed the above assignments. From these data, compound **3** was concluded to be luteolin 7-*O*-[6''-(3'''-hydroxy-4'''-methoxy cinnamoyl)]- β -D-glucopyranoside (**3**).

The structure characterizations of the known compounds, luteolin 7-*O*-(6''-feruloyl)- β -D-glucopyranoside (**4**),⁶ eriodictyol,⁷ miscanthoside,⁸ luteolin,⁷ glucoluteolin,⁸ apigenin-7-glucoside,⁹ chrysin,¹⁰ and apigenin¹¹ were accomplished by direct comparison of their spectroscopic data (¹H-, ¹³C-NMR, and MS) with those reported in the literature.

Experimental

General Procedure Optical rotations were obtained using a JASCO DIP-370 digital polarimeter. UV spectra were determined on a UV 210A spectrometer. IR spectra were recorded on a Bio-Rad PTS-135 spectrophotometer with KBr pellets. Negative FAB-MS were measured with a VG Auto Spec-3000 spectrometer. 1D- and 2D-NMR spectra were run on Bruker AM-400 and DRX-500 instruments with SiMe₄ as an internal standard. Column chromatography was performed on silica gel and silica gel H (200—300 mesh, 10—40 μ m, Qingdao Marine Chemical Inc., China).

Plant Material The Pharmaceutical Factory of Yunnan Institute of Materia Medica provided the samples of *E. bodinieri*.

Extraction and Isolation The powdered air-dried whole plants (6.0 kg) were extracted with 70% aq. Me₂CO (261 \times 3) at r.t. overnight. The extract was partitioned between H₂O and EtOAc. The EtOAc layer (610 g) was

chromatographed on MCI-gel CHP 20P (90% MeOH-H₂O \rightarrow MeOH) to afford Fractions A and B. Fraction A (90% MeOH, 500 g) was subjected to CC over Si gel eluting with a CHCl₃-MeOH 1:0 \rightarrow :1 gradient system to give Fractions 1—15. Fraction 4 (56 g) was further purified by CC over Si gel using CHCl₃-acetone (20:1 \rightarrow 10:3) as eluent to yield chrysin (16 mg) and apigenin (50 mg). Eriodictyol (9 mg) and luteolin (35 mg) were isolated and purified from Fr. 5 (1 g) over Si gel developing with CHCl₃-MeOH 20:1. Fraction 6 was subjected to column chromatography on silica gel (CHCl₃-MeOH 8:2), then semi-preparative HPLC (MeOH-H₂O 37:63) to give **1** (65 mg), **2** (30 mg) and glucoluteolin (4.91 g). Fraction 7 (34 g) was chromatographed on Si gel (CHCl₃-MeOH-H₂O 8:1:0.1 \rightarrow 3:1:0.1), then semi-preparative HPLC (MeOH-H₂O 40:60) to afford **3** (10 mg), **4** (9 mg) and apigenin-7-glucoside (31 mg). Fraction 12 was further purified using CC on RP-18 by eluting with 30% MeOH-H₂O to yield miscanthoside (324 mg).

Eriodictyol 7-*O*-(6''-Feruloyl)- β -D-glucopyranoside (**1**): Yellow amorphous powder; $[\alpha]_D^{20.9}$ -68.3° ($c=0.27$, C₅H₅N); IR (KBr) cm⁻¹: 3420, 2926, 1690, 1642, 1516, 1453, 1272, 1194, 1066; UV λ_{max} (MeOH) nm (log ϵ): 203 (4.82), 285 (4.43), 327 (4.32); FAB-MS (neg.) m/z : 625 (100, [M-H]⁻); HR-FAB-MS (neg.) m/z : 625.1543 (Calcd for C₃₁H₂₉O₁₄, 625.1557); CD ($c=1.05$, MeOH) (mdeg): 354 (-4.09), 302 (+2.27). ¹H- and ¹³C-NMR, see Tables 1 and 2, respectively.

Eriodictyol 7-*O*-[6''-(3'''-Hydroxy-4'''-methoxy cinnamoyl)]- β -D-glucopyranoside (**2**): Yellow amorphous powder; $[\alpha]_D^{20.9}$ -67.9° ($c=0.21$, C₅H₅N); IR (KBr) cm⁻¹: 3425, 2920, 1688, 1635, 1515, 1458, 1270, 1195, 1060; UV λ_{max} (MeOH) nm (log ϵ): 206 (4.72), 280 (4.38), 328 (4.29); FAB-MS (neg.) m/z : 625 (100, [M-H]⁻); HR-FAB-MS (neg.) m/z : 625.1538 (Calcd for C₃₁H₂₉O₁₄, 625.1543); CD ($c=1.10$, MeOH) (mdeg): 352 (-4.38), 299 (+2.08). ¹H- and ¹³C-NMR, see Tables 1 and 2, respectively.

Luteolin 7-*O*-[6''-(3'''-Hydroxy-4'''-methoxy cinnamoyl)]- β -D-glucopyranoside (**3**): Yellow amorphous powder; $[\alpha]_D^{22.0}$ -100.0° ($c=0.09$, C₅H₅N); IR (KBr) cm⁻¹: 3425, 2924, 1689, 1657, 1608, 1515, 1499, 1374, 1261, 1179, 1081; FAB-MS (neg.) m/z : 623 (100, [M-H]⁻); HR-FAB-MS (neg.) m/z : 623.125 (Calcd for C₃₁H₂₇O₁₄, 623.100); ¹H- and ¹³C-NMR, see Tables 1 and 2, respectively.

Acid Hydrolysis of Compounds 1—3 on HPTLC Plate Compounds **1—3** and authentic sugar were individually spotted on a HPTLC precoated plate, and hydrolyzed with concentrated HCl vapor (80 °C water bath for 20 min) followed by co-TLC with authentic sugar developing with CHCl₃-MeOH-H₂O-HOAc (7:3:0.5:1). The HPTLC plate was sprayed with 10% H₂SO₄ for detection. The β -D-glucose was detected with an R_f value of 0.42.

Acknowledgements This project was supported by the Young Academic and Technical Leader Raising Foundation of Yunnan Province (No. 2005py01-32), and the Program for New Century Excellent Talents on University (NECT-06-0824).

References and Notes

- Jiangshu New College of Medicine, "The Dictionary of Chinese Medicine," Shanghai Press of Science and Technology, Shanghai, 1985, p. 489.
- Zhu W. M., He H. P., Wang S., Zuo G. Y., Hao X. J., *Chin. Chem. Lett.*, **13**, 253—256 (2002).
- The whole plant of *E. bodinieri* is the main components of an anti-influenza medicine produced by the Pharmaceutical Factory of Yunnan Institute of Materia Medica.
- Li R. T., Li J. T., Wang J. K., Han Q. B., Zhu Z. Y., Sun H. D., *Helv. Chim. Acta*, **88**, 252—258 (2005).
- Desmond S., Daneel F., Jannie P. J. M., *Phytochemistry*, **66**, 2177—2215 (2005).
- Mizuo M., Kato M., Inuma M., Tanaka T., Kimura A., Ohashi H., Sakai H., *Phytochemistry*, **26**, 2418—2420 (1987).
- Wagner H., Chari V. M., Sonnenbichlen J., *Tetrahedron Lett.*, **21**, 1799—1802 (1976).
- Markham K. R., Ternal B., Stanley R., Geiger H., Mabry T. J., *Tetrahedron*, **34**, 1389—1397 (1978).
- Takeda K., Harborne J. B., Waterman P. G., *Phytochemistry*, **34**, 421—423 (1993).
- Gaydon E. M., Bianchini J. P., *Bull. Soc. Chim., Part II*, **1978**, 43—47 (1978).
- Ternai B., Markham K. R., *Tetrahedron*, **32**, 565—569 (1976).